Compositions for delivery of long-acting Muscarinic antagonist and agonist of long-acting B2 adrenergic receptor. Method of treatment. Associated Systems.MDI

摘要

Item 1: a pharmaceutical ingredient, which can be provided by metered dose inhaler, is characterized in that it includes: a suspension means including acceptable propellant on the pharmaceutical; A plurality of active agent particles, including the active agent selected from an active muscle antagonist (Lama) and an active activator (adrvobta2);And a plurality of respirable suspended particles, where a plurality of active substance particles are connected with a plurality of suspended particles to form a cosspension. The second requirement: according to the first requirement, a pharmaceutical component, which is characterized by that the active agent in the active agent granules is a living human from glycerin, desimi, theotropio, tropio, aclidinio, darotropio and any of their salts, esters, Plasma or drug acceptable solution. The ninth requirement: according to the second requirement, the composition of drugs,It is characterized by suspended particles including penetrating microstructures Item 20: a method for treating lung diseases of patients, which is characterized in that the method includes: providing a dose inhaler containing acceptable cosmetics on drugs, cosmetics including: a suspension method including acceptable propellants on drugs; A plurality of active agent particles, including a selected active agent of an active agent Lama and an active agent Laba; and a plurality of respirable suspended particles,Multiple active agent particles are related to multiple suspended particles, and cosmetics are applied to patients through dose inhalers, In this case, the management of the cosmetic pension includes providing patients with an effective amount of therapeutic active agent Lama or Laba. Requirement No. 43: according to requirement No. 1, a pharmaceutical component, which is characterized by that the active agent in the active agent particles is Laba, which is selected from the active agents of bamitol, clenbuterol, methoxyether, salmeterol, carmoterol and milveterol,2. Amphetamine type stimulants containing saliva or India glycol and any pharmaceutically acceptable salts, esters, isocyanates or solutions thereof in amphetamine derivatives; Requirement No. 64: the method determined in accordance with requirement No. 63, which is characterized by disease or lung disease selected from at least one of the following diseases: asthma, COPD, allergic nephritis, sinusitis, pulmonary conjunctivitis, inflammation, allergy, dyspnea, dyspnea, dyspnea, dyspnea syndrome, Pulmonary hypertension, pulmonary conjunctivitis,Pneumonia is related to chemical fibrosis and pulmonary obstruction, and chemical fibrosis. Requirement No. 86: use metered dose inhalers in accordance with requirement No. 84, It is characterized in that N - (2-hydroxy-5 - (1 - (2-hydroxy-5 - (1-hydroxy-2 - (1 - (4-methoxy) propyl-2-ethyl) phenyl) - 2 - (1 - (4-methoxy) propyl-2-ethyl) phenyl) contains not more than 0.5% propylene in an acceptable medical pension,after subjecting the boat to a temperature of 40 ° C and a relative humidity of 75% for a month. Claim 87: A pharmaceutical composition that can be supplied from a metered dose inhaler, characterized in that it comprises: a suspension medium comprising a pharmaceutically acceptable HFA propellant; a plurality of active agent particles comprising glycopyrrolate, which includes any of its pharmaceutically acceptable salts, esters, isomers or solvates,These active agent particles are included in the suspension medium with enough concentration to provide a kind of proliferative glycerin which can be provided through the dose between about 15 mg and 80 mg and through the action of inhalation dose agent; A number of respirable aerosols, including penetrating microstructures, show an average optimized volume diameter of about 1.5mm between about 10 mm, and these penetrating microstructures combine with a number of active agent particles to form a gap.